Skip to main content
. Author manuscript; available in PMC: 2010 Feb 24.
Published in final edited form as: Biochemistry. 2009 Feb 24;48(7):1474–1480. doi: 10.1021/bi801840s

Figure 2.

Figure 2

Cisplatin-induced p70S6K downregulation is mediated by caspase-3. (a), A549 cells were treated with 10 µM Mg132, 20 µM calpeptin and 20 µM z-VAD for 30 min prior to incubation with 30 μM cisplatin. (b), A549 cells were treated with 20 μM caspase inhibitors for 30 min prior to incubation with 30 μM cisplatin. z-VAD, broad specificity caspase inhibitor; z-VDVAD, caspase-2 inhibitor; z-DEVD, caspase-3 inhibitor; z-IETD, caspase-8 inhibitor; z-LEHD, caspase-9 inhibitor. Cells were processed following treatment with cisplatin for 24 h. Western blot analysis was performed with total cellular extracts using indicated antibodies. GAPDH was used as a loading control. The arrow indicates cleaved p70S6K band. Results are representative of two independent experiments. (c), A549 cells were transfected with control non-targeting siRNA or siRNA SMARTpool against caspase-2 or caspase-3 as described in “Experimental Procedures.” Western blot analysis was performed with total cellular extracts using indicated antibodies. (d), A549 cells transfected with control and caspase-2 siRNA were treated with or without cisplatin for 24 h and Western blot analysis was performed with total cell extracts. GAPDH was used as a loading control. The arrow indicates cleaved p70S6K band. Results are indicative of two independent experiments.